Skip Navigation



Rheumatology Advance Access published online on March 27, 2006
Rheumatology, doi:10.1093/rheumatology/kel072
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
45/10/1197    most recent
kel072v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Kim, H.-R.
Right arrow Articles by Lee, S.-H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kim, H.-R.
Right arrow Articles by Lee, S.-H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2006. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org
Received November 7, 2005
Accepted February 7, 2006

Concise Report

Elevated serum levels of soluble receptor activator of nuclear factors-{kappa}B ligand (sRANKL) and reduced bone mineral density in patients with ankylosing spondylitis (AS)

H.-R. Kim 1, H.-Y. Kim 2, and S.-H. Lee 1 *

1 Division of Rheumatology, Department of Internal Medicine, Konkuk University Hospital, School of Medicine, Konkuk University, Korea
2 Division of Rheumatology, Department of Internal Medicine, Kangnam St Mary's Hospital, The Catholic University of Korea, Seoul, Korea

* To whom correspondence should be addressed.
S.-H. Lee, E-mail: shlee{at}kuh.ac.kr


  Abstract

Objective. To assess bone mineral density (BMD), serum levels of soluble receptor activator of nuclear factors-{kappa}B ligand (sRANKL) and osteoprotegerin (OPG) in patients with ankylosing spondylitis (AS), and to determine their relationships with disease activities.

Methods. Serum levels of sRANKL and OPG in AS were measured by sandwich enzyme-linked immunosorbent assay. The disease activities were determined using Bath Ankylosing Spondylitis Disease Activity Score Index, Bath Ankylosing Spondylitis Functional Index , Bath Ankylosing Spondylitis Metrology Index and Bath Ankylosing Spondylitis Patient Global Score. BMD of femur and lumbar spine was measured by dual energy X-ray absorptiometry. Radiological grading was determined by New York criteria for sacroiliitis and modified Stoke Ankylosing Spondylitis Spine Score.

Results. Osteoporosis and osteopaenia of femoral neck were found in 33 and 41% of patients, respectively. BMD of femoral neck showed negative correlation with disease activity indexes, erythrocyte sedimentation rate and C-reactive protein. The serum sRANKL levels and the ratio of sRANKL to OPG were significantly higher in patients with AS than those of controls. The sRANKL/OPG ratio tended to increase in patients with reduced BMD and radiological findings of active inflammation.

Conclusion. About 74% of AS patients have reduced BMD and this change reflects disease activity. Serum sRANKL levels and sRANKL/OPG ratios are up-regulated in patients with AS and have relationship with BMD and radiological changes. These results suggest that the imbalance between RANKL and OPG might be involved in the pathogenesis and clinical courses of osteoporosis in AS.

Keywords: Ankylosing spondylitis; Osteoporosis; Bone mineral density; Receptor activator of nuclear factors-{kappa}B ligand; Osteoprotegerin..
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.